Published in Hepatitis Weekly, January 17th, 2000
The application proposes administration of PEG-INTRON subcutaneously once weekly for one year.
Schering-Plough previously reported that it has submitted a centralized Marketing Authorization Application for PEG-INTRON to the European Union's (EU) European Agency for the Evaluation of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.